CM
SRRA

Crestline Management’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Crestline Management’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-7,391
Closed -$612K – 303
2018
Q1 		$612K Buy
+7,391
New +$838K 0.08% 185

Other funds holding SRRA

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Crestline Management's SRRA Position: Q2 2018 in Review

Crestline Management sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2018, closing a stake of 7,391 shares — an estimated $612K sold.

Crestline Management first reported a position in SRRA in Q1 2018 and held it in 1 quarter. The position peaked at $612K in Q1 2018. 70 funds tracked by Wall St. Rank hold SRRA as of Q2 2018.

  • Crestline Management reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Crestline Management sold 7,391 Sierra Oncology, Inc. Common Stock shares in Q2 2018, an estimated $612K.
  • Crestline Management first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • Crestline Management's Sierra Oncology, Inc. Common Stock position peaked at $612K in Q1 2018.
  • 70 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2018.

Based on Crestline Management's 13F filing for Q2 2018, filed 14 Aug 2018.